Company: CMND
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112329
Chunk: 57

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 57
---
>

We may issue warrants for
the purchase of shares of our Common Stock. We may issue warrants independently of or together with shares of our Common Stock offered
by any prospectus supplement, and we may attach the warrants to, or issue them separately from, shares of our Common Stock. Each series
of warrants will be issued under a separate warrant agreement to be entered into between us and a bank or trust company, as warrant agent,
all as set forth in the prospectus supplement relating to the particular issue of offered warrants. The warrant agent will act solely
as our agent in connection with the warrant certificates relating to the warrants and will not assume any obligation or relationship of
agency or trust with any holders of warrant certificates or beneficial owners of warrants. The following summaries of certain provisions
of the warrant agreements and warrants do not purport to be complete and are subject to, and are qualified in their entirety by reference
to, all the provisions of the warrant agreement and the warrant certificates relating to each series of warrants which we will file with
the SEC and incorporate by reference as an exhibit to the registration statement of which this prospectus is a part at or prior to the
time of the issuance of any series of warrants.

General

The applicable prospectus
supplement will describe the terms of the warrants, including as applicable:

| ● | the offering price; |

| ● | the aggregate number or amount of underlying securities purchasable upon exercise of the warrants and the exercise price; |

| ● | the number of warrants being offered; |

| ● | the date, if any, after which the warrants and the underlying securities will be transferable separately; |

| ● | the date on which the right to exercise the warrants will commence, and the date on which the right will expire, or the Expiration Date; |

| ● | the number of warrants outstanding, if any; |

| ● | any material Canadian and/or U.S. federal income tax consequences; |

| ● | the terms, if any, on which we may accelerate the date by which the warrants must be exercised; and; |

| ● | any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants. |

Warrants will be offered and
exercisable for U.S. dollars only and will be in registered form only.

Holders of warrants will be
able to exchange warrant certificates for new warrant certificates of different denominations, present warrants for registration of transfer,
and exercise warrants at the corporate trust